ARTICLE | Clinical News
CB001: Development discontinued
February 12, 2007 8:00 AM UTC
VIAC said it will discontinue development of CB001 after data from an open-label, U.S. Phase I/II trial in 10 patients showed no chimerism by days 21-28. VIAC said that chimerism, the presence of dono...